Tissue targeted nanocapsids for oral insulin delivery via drink
| Autor: | R. Holland Cheng, Mo Baikoghli, Chun C Chen |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
medicine.medical_treatment
Insulin delivery Drinking Administration Oral 030209 endocrinology & metabolism 02 engineering and technology Pharmacology medicine.disease_cause Patents as Topic 03 medical and health sciences Subcutaneous injection 0302 clinical medicine Drug Delivery Systems Hepatitis E virus Nanocapsules Diabetes mellitus medicine Diabetes Mellitus Ingestion Animals Humans Hypoglycemic Agents Insulin business.industry General Medicine 021001 nanoscience & nanotechnology medicine.disease Hepatitis E Drug delivery Capsid Proteins 0210 nano-technology business |
| Zdroj: | Pharmaceutical patent analyst. 7(3) |
| ISSN: | 2046-8962 |
| Popis: | For the past eight decades, subcutaneous injection has been the main route used for supplementing the suboptimal insulin secretion for administering insulin as a treatment for diabetes mellitus. Although this method is effective, subcutaneous injections are painful, inconvenient and carry a high risk of infections leading to poor patient compliance. The insulin-encapsulated hepatitis E virus nanoparticle, composed of the noninfectious hepatitis E viral capsid, is expected to deliver insulin from the GI tract to the liver after ingestion. Hepatitis E virus nanoparticle could be the answer to the long search of effective and efficient means to administer insulin orally and the most preferred route of drug delivery with highest patient compliance. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|